These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25870057)

  • 1. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
    Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
    Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
    Sevinsky H; Zaru L; Wang R; Xu X; Pikora C; Correll TA; Eley T
    Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
    Lalezari JP; Latiff GH; Brinson C; Echevarría J; Treviño-Pérez S; Bogner JR; Thompson M; Fourie J; Sussmann Pena OA; Mendo Urbina FC; Martins M; Diaconescu IG; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
    Lancet HIV; 2015 Oct; 2(10):e427-37. PubMed ID: 26423650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
    Nettles RE; Schürmann D; Zhu L; Stonier M; Huang SP; Chang I; Chien C; Krystal M; Wind-Rotolo M; Ray N; Hanna GJ; Bertz R; Grasela D
    J Infect Dis; 2012 Oct; 206(7):1002-11. PubMed ID: 22896665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
    Landry I; Zhu L; Abu Tarif M; Hruska M; Sadler BM; Pitsiu M; Joshi S; Hanna GJ; Lataillade M; Boulton DW; Bertz RJ
    Antimicrob Agents Chemother; 2016 May; 60(5):2782-9. PubMed ID: 26902761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
    Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
    Song I; Borland J; Chen S; Lou Y; Peppercorn A; Wajima T; Min S; Piscitelli SC
    Br J Clin Pharmacol; 2011 Jul; 72(1):103-8. PubMed ID: 21342217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
    AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults.
    Hiransuthikul A; Thammajaruk N; Techatanawat I; Karachot B; Chuasuwan B; Manamuti C; Duereh M; Sawpitiporn M; Sophonphan J; Gatechompol S; Avihingsanon A; Bowonwattanuwong C; Ruxrungtham K;
    Antivir Ther; 2018; 23(8):699-703. PubMed ID: 30265243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
    Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
    HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects.
    Calderón MM; Penzak SR; Pau AK; Kumar P; McManus M; Alfaro RM; Kovacs JA
    Clin Infect Dis; 2016 Apr; 62(8):1036-1042. PubMed ID: 26797214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
    Burger DM; Agarwala S; Child M; Been-Tiktak A; Wang Y; Bertz R
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3336-42. PubMed ID: 17005814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
    Mills A; Mildvan D; Podzamczer D; Fätkenheuer G; Leal M; Than S; Valluri SR; Craig C; McFadyen L; Vourvahis M; Heera J; Valdez H; Rinehart AR; Portsmouth S
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):164-70. PubMed ID: 23187936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
    Hulskotte EG; Feng HP; Xuan F; van Zutven MG; Treitel MA; Hughes EA; O'Mara E; Youngberg SP; Wagner JA; Butterton JR
    Clin Infect Dis; 2013 Mar; 56(5):718-26. PubMed ID: 23155151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.
    Zhang J; Chung E; Yones C; Persson A; Mahnke L; Eley T; Xu X; Bertz R
    Antivir Ther; 2011; 16(2):157-64. PubMed ID: 21447864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.